Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,340
  • Shares Outstanding, K 2,227
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,770 K
  • 60-Month Beta 1.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.45
Trade MBRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -2.40
  • Number of Estimates 1
  • High Estimate -2.40
  • Low Estimate -2.40
  • Prior Year -4.20
  • Growth Rate Est. (year over year) +42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.34 +41.24%
on 03/26/24
10.35 -40.77%
on 03/11/24
-3.02 (-32.99%)
since 02/28/24
3-Month
4.34 +41.24%
on 03/26/24
15.75 -61.08%
on 01/03/24
-5.12 (-45.51%)
since 12/28/23
52-Week
4.34 +41.24%
on 03/26/24
24.75 -75.23%
on 04/18/23
-8.12 (-56.97%)
since 03/28/23

Most Recent Stories

More News
JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023

- Live video webcast interactive Q&A with participating companies -

EVFM : 0.0272 (+4.62%)
GRI : 0.7860 (+1.29%)
MBRX : 6.18 (+11.55%)
XBIO : 3.84 (-3.64%)
AREC : 1.4800 (+2.07%)
CNSP : 0.3700 (unch)
NVNO : 5.40 (+2.27%)
PALI : 0.3924 (-0.73%)
Moleculin to Participate in the Virtual Investor Ask the CEO Conference

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug...

MBRX : 6.18 (+11.55%)
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

MBRX : 6.18 (+11.55%)
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a growing pipeline, including...

MBRX : 6.18 (+11.55%)
Moleculin Announces New Positive Independent Report of No Cardiotoxicity in Annamycin

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 6.18 (+11.55%)
Moleculin Announces Abstract Accepted for Poster Presentation at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 6.18 (+11.55%)
Moleculin to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 6.18 (+11.55%)
Moleculin Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline,...

MBRX : 6.18 (+11.55%)
Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones

– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML...

MBRX : 6.18 (+11.55%)
Moleculin Retains Shareholder Intelligence Services, LLC to Investigate Potential Naked Short Selling

/PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug...

MBRX : 6.18 (+11.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

3rd Resistance Point 6.84
2nd Resistance Point 6.26
1st Resistance Point 5.90
Last Price 6.18
1st Support Level 4.96
2nd Support Level 4.39
3rd Support Level 4.03

See More

52-Week High 24.75
Fibonacci 61.8% 16.95
Fibonacci 50% 14.55
Fibonacci 38.2% 12.14
Last Price 6.18
52-Week Low 4.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar